Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Arcoxia/Cardiome Oxyprim for gout

Executive Summary

FDA's Arthritis Advisory Committee will discuss NDAs for Merck's Arcoxia for acute gout and Cardiome's Oxyprim in the treatment of gout at its June 2-3 meeting. On June 2, the committee will consider Oxyprim and trial design/endpoints for chronic gout. Arcoxia will be discussed on June 3 in conjunction with trial endpoints and design for acute gout. The topic was previously scheduled for discussion on Nov. 13, 2003, but the meeting was postponed. The meeting will be held at CDER's advisory committee conference room at 5630 Fishers Lane in Rockville, Md. at 8 a.m...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS043824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel